Form 4: QuidelOrtho Director Receives Equity Grant

Michael Edward L. reports receipt of restricted stock units and conversion of existing units as part of his director compensation at QuidelOrtho Corp.

Summary

• Michael Edward L., a Director at QuidelOrtho Corp (QDEL), reported transactions related to equity compensation on June 25, 2026.
• He received 15,532 restricted stock units (RSUs) as part of his director fees.
• Additionally, 3,513 restricted stock units were converted, and 1,053 restricted stock units were received as a premium under a deferred compensation program.
• These RSUs represent the right to receive one share of QuidelOrtho Corporation common stock upon vesting.
• The initial grant of 15,532 RSUs is set to vest on June 25, 2027.
• The converted and premium RSUs are subject to elected deferral schedules.
• Specifically, 878 shares from the converted RSUs vested on June 25, 2026, with subsequent vesting dates on September 25, 2026, December 25, 2026, and March 25, 2027, for 878, 878, and 879 shares respectively.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine director compensation and does not provide new financial performance data or strategic shifts.

Positives

• Director compensation is being provided in the form of equity, aligning director interests with shareholders.
• The reporting person has received a significant number of restricted stock units, indicating continued engagement and commitment.
• Vesting schedules are clearly defined, providing a roadmap for equity realization.

Negatives

• The filing does not contain financial performance data, making it difficult to assess the company's overall health.
• Details on the specific value of the equity grants are not provided in this filing.

Risks

• The value of the restricted stock units is subject to the future performance of QuidelOrtho Corporation's stock price.
• Vesting schedules and deferral elections mean that the reporting person will not have immediate full control or benefit from all awarded shares.

Future Outlook

The filing primarily concerns equity grants and vesting schedules, with no specific forward-looking financial guidance provided. The future outlook for the value of the granted equity is tied to the company's stock performance.

Management Comments

• The restricted stock units were received in lieu of cash payments for retainer and Board of Director service-related fees under a deferred compensation program.
• Release of vested restricted stock units will occur according to the elected deferral schedule.

Industry Context

StockSavvy.ai notes that the use of restricted stock units for director compensation is a common practice in the biotechnology and diagnostics industry, aiming to align executive and director interests with long-term shareholder value.

Related Party Transactions

• The restricted stock units were issued as compensation to a director (Michael Edward L.) for services rendered, which is a standard related-party transaction for compensation purposes.

Stakeholder Impact

• Shareholders: The equity grants align director incentives with shareholder interests, potentially leading to decisions that enhance long-term stock value.
• Employees: While not directly impacting employees, the compensation structure for directors reflects the company's overall approach to incentivizing key personnel.
• Management: The filing provides transparency on director compensation, a key aspect of corporate governance.

Next Steps

• Vesting of restricted stock units according to the specified schedules.
• Potential release of vested shares based on elected deferral schedules.

Key Dates

Keywords

Form 4, SEC Filing, QuidelOrtho Corp, QDEL, Michael Edward L., Director, Restricted Stock Units, RSU, Equity Grant, Beneficial Ownership, Deferred Compensation